1. Blood fibrocytes are associated with severity and prognosis in COVID-19 pneumonia
- Author
-
Ghanem, Mada, Homps-Legrand, Méline, Garnier, Marc, Morer, Lise, Goletto, Tiphaine, Frija-Masson, Justine, Wicky, Paul-Henri, Jaquet, Pierre, Bancal, Catherine, Hurtado-Nedelec, Margarita, de Chaisemartin, Luc, Jaillet, Madeleine, Mailleux, Arnaud, Quesnel, Christophe, Poté, Nicolas, Debray, Marie-Pierre, de Montmollin, Etienne, Neukirch, Catherine, Borie, Raphael, Taillé, Camille, Crestani, Bruno, Covid Cohort Study Group, French, Andréjak, Claire, Physiopathologie et Epidémiologie des Maladies Respiratoires (PHERE (UMR_S_1152 / U1152)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'Anesthésie réanimation [CHU Tenon], CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Pasteur [Paris] (IP), Agents infectieux, résistance et chimiothérapie - UR UPJV 4294 (AGIR ), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, CHU Amiens-Picardie, French COVID cohort study group, ANR-21-CO12-0007,FIBROCO,Implication des fibrocytes circulants dans la physiopathogénie et le pronostic de la pneumopathie sévère au cours du COVID-19(2021), HAL-SU, Gestionnaire, and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
- Subjects
Male ,Physiology ,CD34 ,Severity of Illness Index ,Gastroenterology ,law.invention ,0302 clinical medicine ,law ,Fibrocyte ,Aged, 80 and over ,0303 health sciences ,[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology ,medicine.diagnostic_test ,Middle Aged ,Intensive care unit ,3. Good health ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Cytokines ,Female ,Research Article ,Adult ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,CCL2 ,03 medical and health sciences ,Antigens, CD ,Physiology (medical) ,Internal medicine ,Severity of illness ,medicine ,Humans ,COVID-19 pneumonia ,Aged ,030304 developmental biology ,Serum Amyloid A Protein ,Blood Cells ,Lung ,SARS-CoV-2 ,business.industry ,COVID-19 ,Cell Biology ,medicine.disease ,Blood Cell Count ,Pneumonia ,Bronchoalveolar lavage ,fibrocyte ,prognosis ,Tomography, X-Ray Computed ,business ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
Increased blood fibrocytes are associated with a poor prognosis in fibrotic lung diseases. We aimed to determine whether the percentage of circulating fibrocytes could be predictive of severity and prognosis during coronavirus disease 2019 (COVID-19) pneumonia. Blood fibrocytes were quantified by flow cytometry as CD45+/CD15−/CD34+/collagen-1+ cells in patients hospitalized for COVID-19 pneumonia. In a subgroup of patients admitted in an intensive care unit (ICU), fibrocytes were quantified in blood and bronchoalveolar lavage (BAL). Serum amyloid P (SAP), transforming growth factor-β1 (TGF-β1), CXCL12, CCL2, and FGF2 concentrations were measured. We included 57 patients in the hospitalized group (median age = 59 yr [23–87]) and 16 individuals as healthy controls. The median percentage of circulating fibrocytes was higher in the patients compared with the controls (3.6% [0.2–9.2] vs. 2.1% [0.9–5.1], P = 0.04). Blood fibrocyte count was lower in the six patients who died compared with the survivors (1.6% [0.2–4.4] vs. 3.7% [0.6–9.2], P = 0.02). Initial fibrocyte count was higher in patients showing a complete lung computed tomography (CT) resolution at 3 mo. Circulating fibrocyte count was decreased in the ICU group (0.8% [0.1–2.0]), whereas BAL fibrocyte count was 6.7% (2.2–15.4). Serum SAP and TGF-β1 concentrations were increased in hospitalized patients. SAP was also increased in ICU patients. CXCL12 and CCL2 were increased in ICU patients and negatively correlated with circulating fibrocyte count. We conclude that circulating fibrocytes were increased in patients hospitalized for COVID-19 pneumonia, and a lower fibrocyte count was associated with an increased risk of death and a slower resolution of lung CT opacities.
- Published
- 2021